| Age at diagnosis (years) |
53.3 (8.9) |
55.3 (8.4) |
51.4 (9.0) |
<0.0001 |
|
Sex:
|
|
|
|
|
| Men |
308 (58.1) |
222 (85.4) |
86 (31.7) |
<0.001 |
| Women |
222 (41.9) |
37 (14.6) |
185 (68.3) |
|
Education:
|
|
|
|
|
| No formal education |
201 (37.9) |
75 (29.0) |
126 (46.5) |
0.001 |
| Up to 4 years |
77 (14.5) |
45 (17.4) |
32 (11.8) |
| 5-12 years |
123 (23.2) |
71 (27.4) |
52 (19.2) |
| Graduation and above |
45 (8.5) |
25 (9.6) |
20 (7.4) |
| Missing |
84 (15.8) |
43 (16.6) |
41 (15.1) |
|
Pre-treatment clinical extent:
|
|
|
|
|
| Localised/Direct extension |
140 (26.2) |
72 (27.8) |
68 (25.1) |
<0.001 |
| Direct extension with regional nodes |
90 (17.0) |
66 (25.5) |
24 (8.9) |
| Distant metastasis/Advanced/ Recurrent |
258 (48.7) |
106 (40.9) |
152 (56.1) |
| Missing |
42 (7.9) |
15 (5.8) |
27 (10.0) |
|
Treatment receipt:
|
|
|
|
|
| Never treated |
178 (33.6) |
35 (13.5) |
143 (52.8) |
<0.001 |
| Single Modality |
201(37.9) |
130 (50.2) |
71 (26.2) |
| Combined |
103 (19.4) |
78 (30.1) |
25 (9.2) |
| Missing |
48 (9.1) |
16 (6.2) |
32 (11.8) |
|
Prospective status:
|
|
|
|
|
| Followed-up |
354 (66.7) |
175 (67.4) |
179 (66.0) |
0.711 |
| Lost to follow-up |
172 (32.5) |
84 (32.6) |
88 (32.5) |
| Refused to participate |
04 (0.7) |
Nil |
04 (1.5) |
|
Vital status § in 2016:
|
|
|
|
|
| Survival |
28 (7.9) |
17 (9.7) |
11 (6.1) |
0.214 |
| Death |
326 (92.1) |
158 (90.3) |
168 (93.8) |